Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$8.06 USD
+0.04 (0.50%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.06 0.00 (0.00%) 6:20 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Zevra Therapeutics, Inc. [ZVRA]
Reports for Purchase
Showing records 1 - 20 ( 35 total )
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Presents New Arimoclomol and OLPRUVA Results at SSIEM 2024 Annual Meeting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2Q24: Very Well Funded, Expecting Arimoclomol Approval, PRV Receipt Sale
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
AdComm Panel Votes 11-5 Favoring Arimoclomol For NPC, We Expect Approval
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Decisive Positive Arimoclomol AdCom Vote; Raise PT to $18 Ahead of Sept 21 PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Solid Phase 2 KP1077 Data Presented At AASM Sleep Inform Phase 3 Design
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
1Q24: Commercial Pipeline Progressing Well, Comfortably Funded Into 2026
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q EPS Optics Not Material; Looking Forward to Transformational 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q23: KP1077 Phase 2 Win, Arimoclomol PDUFA Set, Another AZSTARYS Milestone
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol PDUFA Extension Not a Material Delay; Perhaps Even Bolsters View on Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol PDUFA Date Pushed to Sept 21, 2024, Not Material In Our View
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Updating Our Model For the New Zevra; Target to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Arimoclomol NDA Resubmitted On Time, Expecting Late 2Q24 PDUFA Date
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
3Q23: Arimoclomol NDA ACER Acquired By YE23, IH Data 1H24, Well Funded; PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J